ICCC Q4 2020 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+3.1% YoY

Gross Profit

$2M43.3% margin

Operating Income

-$634,000-16.9% margin

Net Income

$189,0005.0% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$156,248

Free Cash Flow

-$128,431

Stock-Based Comp.

$56,700

Balance Sheet

Total Assets

$40M

Total Liabilities

$12M

Stockholders' Equity

$28M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	+3.1%
Gross Profit	$2M	$2M	-11.8%
Operating Income	-$634,000	-$242,465	-161.5%
Net Income	$189,000	-$310,451	+160.9%